Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    ESMO open. 2017 Jan 6. doi: 10.1136/esmoopen-2016-000127. pii: esmoopen-2016-000127. pmc: PMC5548978
    The European Cancer Patient's Bill of Rights, update and implementation 2016.
    Højgaard L1,  Löwenberg B2,  Selby P3,  Lawler M4,  Banks I5,  Law K6,  Albreht T7,  Armand JP8,  Barbacid M9,  Barzach M10,  Bergh J11,  Cameron D12,  Conte P13,  de Braud F14,  de Gramont A15,  De Lorenzo F16,  Diehl V17,  Diler S18,  Erdem S19,  Geissler J20,  Gore-Booth J21,  Henning G22,  Horgan D23,  Jassem J24,  Johnson P25,  Kaasa S26,  Kapitein P27,  Karjalainen S28,  Kelly J29,  Kienesberger A30,  La Vecchia C31,  Lacombe D32,  Lindahl T33,  Luzzatto L34,  Malby R35,  Mastris K36,  Meunier F37,  Murphy M38,  Naredi P39,  Nurse P40,  Oliver K41,  Pearce J42,  Pelouchov J43,  Piccart M44,  Pinedo B45,  Spurrier-Bernard G46,  Sullivan R47,  Tabernero J48,  Van de Velde C49,  van Herk B50,  Vedsted P51,  Waldmann A52,  Weller D53,  Wilking N54,  Wilson R55,  Yared W56,  Zielinski C57,  Zur Hausen H58,  Le Chevalier T59,  Johnston P60
    Author information
    1Danmarks Grundforskningsfond, Kobenhavn, Denmark.
    2Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
    3European Cancer Concord, Leeds, UK.
    4Queen's University Belfast, Belfast, UK.
    5European Cancer Concord, Leeds, UK.
    6European Cancer Concord, Leeds, UK.
    7Institut za varovanje zdravja Republike Slovenija, Ljubljana, Slovenia.
    8Gustave Roussy, Villejuif, France.
    9Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
    10IHU Strasbourg Board of Trustees, Strasbourg, France.
    11Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
    12Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, UK.
    13Istituto Oncologico Veneto, Padova, Italy.
    14Medical Oncology Division, National Cancer Institute, Milan, Italy.
    15Department of Oncology, Institut Hospitalier Franco-Britannique, Levallois-Perret, France.
    16Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy.
    17Internal Medicine, Universitat zu Koln, Koln, Germany.
    18Myeloma Patients Europe, Istanbul, Turkey.
    19Europa Donna, Milan, Italy.
    20Leukemia Patient Advocates Foundation, Berne, Switzerland.
    21EuropaColon, London, UK.
    22EuropaColon, London, UK.
    23European Alliance for Personalised Medicine, Brussels, Belgium.
    24Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
    25Department of Medical Oncology, University of Southampton, Southampton, UK.
    26Institute of Cancer Research and Molecular Medicine, Norges teknisk-naturvitenskapelige universitet, Trondheim, Norway.
    27Inspire2Live, Amsterdam, The Netherlands.
    28Syopajarjestot, Helsinki, Finland.
    29Association of European Cancer Leagues, Brussels, Belgium.
    30Austrian Childhood Cancer Organisation, Vienna, Austria.
    31Department of Clinical Sciences and Community Health, Universita degli Studi di Milano, Milano, Italy.
    32European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
    33Francis Crick Institute, London, UK.
    34Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
    35School of Health and Social Care, London South Bank University, London, UK.
    36Europa Uomo, Antwerp, Belgium.
    37European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
    38European Cancer Concord, Society for Translational Oncology, Durham, North Carolina, USA.
    39Goteborgs Universitet, Goteborg, Sweden.
    40Francis Crick Institute, London, UK.
    41International Brain Tumour Alliance, Tadworth, UK.
    42Lymphoma Association, Aylesbury, UK.
    43European Cancer Patient Coalition, Brussels, Belgium.
    44Institut Jules Bordet, Bruxelles, Belgium.
    45VuMC Cancer Center, Amsterdam, The Netherlands.
    46Melanoma Patient Network Europe, Paris, France.
    47Institute of Cancer Policy, Kings Health Partners Integrated Cancer Centre, London, UK.
    48Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
    49Department of Surgery, Leids Universitair Medisch Centrum, Leiden, The Netherlands.
    50European Cancer Organisation, Brussels, Belgium.
    51Institute for Public Health and Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark.
    52Leukaemiehilfe RHEIN-MAIN, Rüsselsheim, Germany.
    53Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
    54Department of Oncology, Karolinska Institutet, Stockholm, Sweden.
    55Sarcoma Patients EuroNet EV, Bad Nauheim, Germany.
    56Association of European Cancer Leagues, Brussels, Belgium.
    57Comprehensive Cancer Center and Department of Medicine I, Medical University of Vienna, Vienna, Austria.
    58German Cancer Research Centre, University of Heidelberg, Heidelberg, Germany.
    59European Cancer Concord, Leeds, UK.
    60Queen's University Belfast, Belfast, UK.
    Abstract

    In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. The key aspects of working towards implementing the BoR are:Agree our high-level goal. The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.


    KEYWORDS: Bill of Rights, Cancer Concord, Cancer outcomes

    Publikations ID: 28848664
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt